/
Biological products, (no diagnostic substances) company · DE · FY ends Dec · Revenue $23M · -27.27% margin · -$26M FCF
Margins and capital returns are both well above average: 29.69% operating margin, ROIC at 128.41%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 6.3% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$51M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$23M
▼ -6.3% YoY
Net Income (TTM)
-$9M
▲ +138.3% YoY
Op. Margin
-27.27%
▲ +94.4pp YoY
ROIC
-36.19%
▲ +252.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▲ +26.1% YoY
Op. Cash Flow (TTM)
-$26M
▲ +25.9% YoY
Net Debt
$2M
Cash & Equiv.
$8M
3Y CAGR: +23.9%
Continue Research